Sreelakshmi24’s Blog

where life is all about learning

Archive for May 2009

Carotino India launches rich premium red cooking oil ‘Carotino’

leave a comment »

For the health conscious, here is a cooking oil that can be a vital ingredient to all your recipes.

Carotino India Pvt Ltd has
formally launched its anti-oxidant rich premium red cooking oil Carotino in the state of Maharashtra.

Carotino is:

  • the first and only cooking oil in India that has natural carotenes.
  • a highly nutritious and 100% natural oil with a blend of canola oil & red palm fruit extract.
  • is cholesterol free and rich in natural Beta-Carotenes, Vitamin E, Omega 3, 6 Essential Fatty Acids, Co-Enzyme Q10 and Lycopene.
  • does not contain harmful trans-fatty acids.

    Carotenes and Vitamin E in Carotino act as scavengers of damaging free-radicals and play a protective role in ageing, atherosclerosis and cancer.

    The oil is already available in 1500 retail outlets in Mumbai and around 500 outlets in Pune and will be made available across at all leading retail chains across the country.
    The 500ml of the bottle cost R.185/-.  

    For more details visit:

Written by sreelakshmi

30 May, 2009 at 1:36 pm

Piramal Healthcare Launches Supractiv Complete – A Total Nutritional Supplement

with 68 comments

The nutritional supplement market is the largest segment in the OTC market accounting for over 45% of the OTC products in India. In fact this segment has witnessed a rapid rise in the last few years and is growing at a healthy growth rate of about 12%.

Piramal Healthcare Limited, one of India’s largest integrated healthcare companies launched Supractiv Complete – a total nutritional supplement. Supractiv Complete is rich in many nutrients such as Glutamine, Zinc, Vitamin B-Complex, Vitamins C, Vitamin E, Ginseng, Calcium, Amino Acids and Antioxidants.

Supractiv Complete works on supporting the whole body for nutrition rather than providing only a select benefit, like energy or immunity. Supractiv Complete not only has the right ingredients but also has them in optimal quantities. Its formulation has been prepared by taking into consideration the Recommended Daily Allowance suggested by the Indian Council of Medical Research. One Supractiv Complete a day has nutrients that will provide mental agility, immunity, heart health, stamina, vitality and muscle & bone strength.

A consumer trial conducted by Piramal Healthcare in accordance with a renowned research agency amongst 900 respondents showed that over 98% of them felt a positive discernible difference with Supractiv Complete in just 6 days.

Highlighting the need for a complete nutritional supplement in India, Dr. Swati Piramal, Director, Piramal Healthcare Ltd., said, “Our dietary habits have changed drastically over the years, thanks increasingly to our changing lifestyles. This has rendered our everyday diet deficient in vital nutrients. Hence, there is a pronounced need for nutritional supplement in Indians. At Piramal Healthcare, we believe in reducing the burden of disease and fostering healthy lives. Propelled by our core values of Knowledge Action Care, we continuously strive to apply breakthrough innovations to provide quality products to our end customers. The idea behind launching Supractiv Complete was to empower the consumers to make an informed choice about their nutritional supplements.”

Supractiv Complete is available in a uniquely designed packaged jar of 30 and a convenient trial pack of 10. The clutter breaking packaging not only serves to attract the consumer but also works towards explaining the product, its attributes and the manner in which it works on the human body. Priced between Rs. 60 & 180, Supractiv Complete will be available shortly at chemists’ stores across India.

Written by sreelakshmi

27 May, 2009 at 10:52 pm

GARDASIL® is First Cervical Cancer Vaccine to Receive WHO Pre-qualification

leave a comment »

Cervical cancer is the second most common cancer among women worldwide. Almost 80 percent of cervical cancer cases occur in developing countries.
Human papillomavirus (HPV) is estimated to cause about half a million new cervical cancer cases every year, with a majority affecting women in developing countries. For most women, HPV goes away on its own, however, for some, certain high-risk types of HPV, if unrecognized and untreated, can lead to cervical cancer.
HPV types 16 and 18 cause approximately 70 percent of cervical cancer cases. Not all vulvar and vaginal cancers are caused by HPV and the exact number of cases caused by HPV types 16 and 18 is unknown. However, it is estimated that HPV types 16 and 18 account for 40-50 percent of vulvar cancers and about 70 percent of vaginal cancer. Genital warts are abnormal skin growths caused by HPV, particularly types 6 and 11, which cause more than 90 percent of genital warts.

Now for some good news:

[Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], Merck Sharp & Dohme’s cervical cancer vaccine, has been awarded World Health Organization (WHO) pre-qualification. GARDASIL® is the first cervical cancer vaccine to receive WHO pre-qualification.

WHO pre-qualification means that GARDASIL® is now eligible for procurement by the United Nations Children’s Fund (UNICEF) and other United Nations (UN) agencies including the Pan American Health Organization (PAHO), for use in national immunization programs.

“We recognize the significant impact cervical cancer has on women and families, especially in the developing world, which is why Merck Sharp & Dohme is committed to improving access to innovative vaccines like GARDASIL®,” said Margaret G. McGlynn, president, Merck Sharp & Dohme Vaccines and Infectious Diseases. “WHO pre-qualification is an important step in helping to ensure greater global access to GARDASIL® and to help protect against cervical cancer and other HPV-related diseases caused by HPV types 6, 11, 16 and 18 in more countries throughout the world.”

WHO pre-qualification aims to ensure that vaccines meet WHO standards of quality, safety and efficacy, which in conjunction with other criteria, is used by the UN and other agencies to make purchasing decisions.

“Cervical cancer is a significant burden in developing countries. WHO pre-qualification of an HPV vaccine signifies a move to help protect young women and improve access to better health care, particularly in the poorest countries,” comments Graça Machel, Founder and President of the Foundation for Community Development (FDC), Mozambique and a passionate advocate for women’s health.


GARDASIL® is currently indicated for use in girls and young women 9 through 26 years of age for the prevention of cervical cancers, vulvar and vaginal pre-cancers caused by HPV types 16 and 18; genital warts caused by HPV types 6 and 11; and precancerous or dysplastic lesions caused by HPV types 6, 11, 16 and 18. HPV types 16 and 18 are responsible for approximately 70 percent of cervical cancer cases and HPV types 6 and 11 are responsible for approximately 90 percent of genital warts and about 10 percent of low-grade cervical changes/lesions/dysplasias.

GARDASIL® is contraindicated in individuals with hypersensitivity, including severe allergic reactions to yeast, or after a previous dose of GARDASIL®

About access to GARDASIL® in the developing world

WHO pre-qualification is a significant part of Merck Sharp & Dohme’s approach to accelerating access to GARDASIL® in the developing world through four key pillars:

  • Innovation
  • Partnerships
  • Pricing
  • Implementation

This development follows the recent WHO position paper on the use of HPV vaccines.

Merck Sharp & Dohme will offer GARDASIL® to the public sectors of GAVI-eligible countries at a price at which we do not profit. Additionally, Merck Sharp & Dohme is exploring several ways to further reduce product cost for the developing world, including manufacturing efficiencies and reduction of royalties paid out to licensors on GARDASIL® doses sold in the developing world.

In 2007, Merck Sharp & Dohme made a commitment to donate at least 3 million doses of GARDASIL® over five years to help address the problem of HPV infection in under-resourced communities through the GARDASIL® Access Program which is managed by Axios Healthcare Development. In February 2009, the first doses of the donated GARDASIL® were shipped.

Additionally, Merck Sharp & Dohme is partnering with PATH, an international non-profit organization, to conduct demonstration projects of GARDASIL® in the developing world by providing vaccine and technical support at no cost. These demonstration projects are designed to support the accelerated availability of cervical cancer vaccines in the world’s least-developed countries. The projects are complete in Peru and ongoing in Vietnam and India.

Merck Sharp & Dohme is also sharing clinical data on GARDASIL®, HPV epidemiology and cervical cancer rates from studies done in 41 countries and more than 38,000 patients with health authorities, governments, non-governmental organizations and physicians around the world.

Additional important information about GARDASIL®

  • The health care provider should inform the patient, parent or guardian that vaccination does not substitute for routine cervical cancer screening.
    Women who receive GARDASIL® should continue to undergo cervical cancer screening.
  • GARDASIL® is not recommended for use in pregnant women.
  • GARDASIL® is not intended to be used for treatment of active genital warts, cervical, vaginal and vulvar pre-cancers, cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN) or vaginal intraepithelial neoplasia (VaIN).
  • GARDASIL® has not been demonstrated to provide protection against disease from vaccine and non-vaccine HPV types to which a woman has previously been exposed through sexual activity. GARDASIL® has not been shown to protect against diseases due to HPV types not contained in the vaccine.
  • Not all vulvar and vaginal cancers are caused by HPV and GARDASIL® protects only against those vulvar and vaginal pre-cancers caused by HPV 16 and 18. Vaccination with GARDASIL® may not result in protection in all vaccine recipients.
    In clinical studies for GARDASIL®, headache was the most commonly reported adverse reaction. Common adverse reactions that were observed at a frequency of at least 1 percent among recipients of GARDASIL® and also greater than those observed among recipients of control group, respectively, were pain, swelling, erythema, fever, nausea, pruritis, dizziness and bruising. In addition, syncope has been reported following vaccination with GARDASIL®, sometimes resulting in falling with injury: observation for 15 minutes after administration is recommended.

Dosage and administration for GARDASIL®

GARDASIL® is a ready-to-use, three-dose, intramuscular vaccine. GARDASIL® should be administered in three separate intramuscular injections in the deltoid region of the upper arm or in the higher anterolateral area of the thigh. The following dosage schedule is recommended: first dose at elected date, second dose two months after the first dose and the third dose six months after the first dose.

GARDASIL® is approved in 111 countries

GARDASIL® has been approved in 111 countries, 23 of which are GAVI-eligible, and additional applications are currently under review with regulatory agencies in more countries around the world.

DesignTech Systems to provide solutions to Nairobi’s Coptic Hospital

leave a comment »

DesignTech Systems bags ERP order from Kenya Hospital and two clinical units


DesignTech Systems Limited, leading Product Lifecycle Management, engineering design firm and healthcare solution provider, has bagged an international contract. After delivering its Enterprise Resource Planning (ERP) solution to over a dozen hospitals across India, DesignTech has now got a contract for its ERP installation in one of the largest private hospitals in Kenya’s capital Nairobi. This is DesignTech’s first international project which is to be installed in May.

Mr Vikas Khanvelkar managing director DesignTech Systems Limited said “We have received an order from Coptic Hospital in Nairobi to install the ERP solution developed by our healthcare team. Coptic Hospital is a 250-bed specialty hospital. “

The ERP will also be installed at the two small clinical units run by the group. Asclepius, the ERP developed by DesignTech is a comprehensive hospital management system that takes care of the entire operation within a hospital set-up. Right from patient’s registration to blood bank details and billing procedure, all processes are integrated in the 42-module software

“We could win over the competition because we were able to deliver state-of-the-art technology such as ‘n’ level distributed architecture through our products; thus not only were we able to deliver performance but make sure to protect customer’s cost of ownership for years to come” said Mr. Sachin Chougule, Director, DesignTech Systems.

Asclepius is a comprehensive range of solutions that not only manages and provides all the data but also configures and executes workflows. Asclepius is scalable to meet the needs of small, big and growing clinics and medicals hospitals. DesignTech Systems Limited is also in talks with leading hospitals in other African countries for the same project.

For more information visit:


Written by sreelakshmi

25 May, 2009 at 8:12 pm

Lifebuoy organises Health Rally for awareness of Swine Flu

leave a comment »


Holding placards, shouting slogans enthusiastically, scores of people joined a rally organized for awareness on Swine Flu by India’s largest Health & Hygiene soap brand, Lifebuoy in Hyderabad. Amongst the eminent people present at the event were Mr. L.V. Subramanyam (IAS), Principal Secretary, Medical and Health, Govt. of Andhra Pradesh, who flagged off the rally, Dr Subhakar Kandi, MD FCCP (USA) State Coordinator H1N1 Influenza, Dr. Myriam Sidibe (Dr PH), Global Social Mission Manager, Lifebuoy. The walk was held in support with the leading twin city NGO, Concern for Twin Cities. It also saw an active support of various other NGOs & Social organizations like the Lions Club, Freemasons, Walkers, SIP Academy, Jaycees, Indira Park’s Walker Association, Allipuram Foundation, Smile Foundation, MV Foundation, and many more.

Dr. Subhakar gave an overview on the H1N1 virus and in very simple terms explained about Swine Flu. He also spoke about the interventions required to protect the spread of the endemic. He apprised the public on the simple techniques to safeguard oneself from infections and spread of disease, the most accessible being the act of washing hands correctly. Washing hands regularly with soap and water can protect against both direct (for example, shaking hands with an infected person who has touched his mouth or nose) and indirect contact (for example, touching a doorknob handled by an infected person) with the flu virus. The doctor also said, “In a recent study on Child Health conducted by Lifebuoy, it was distressing to see that Hyderabad was the only city to fall beneath the average country score from the 4 southern states. The concern that came out in the study was around minor illnesses that seemed to bother mothers across the country. Minor illnesses are mostly classified as colds, coughs, normal flu, diarrhoea etc. It is extremely important to practice and maintain good hygiene habits, irrespective of an epidemic. Inculcating the habit of regular hand wash can help lower the risk of catching various infections and hence make us healthier.”

Mr. Subramanyam spoke about the pro-active measures taken by the Govt. of Andhra Pradesh in restricting the disease. He said, “It is an excellent initiative undertaken by the Lifebuoy in creating awareness around Swine Flu and bringing forth issues and concerns of the virus. Such programmes not only help in spreading the right message but also help in controlling anxiety levels and reduce panic amongst public. We are extremely happy that Lifebuoy has extended a helping hand to support the cause of public health”

Dr. Sidbi from Lifebuoy said, “It is overwhelming to see such an enthusiastic support from the lovely Hyderabadis. As this is the first case detected in the country, we felt the need to reach out to larger audience and spread awareness about the incurable virus. The govt. and the doctors here are doing an excellent job and we as Lifebuoy felt it was our duty too as a Health and Hygiene brand to extend our help in our own way towards their efforts, which is why this public awareness rally. We believe that a simple habit change like washing hands at least 5 times a day could go a long way in prevention of various infections and diseases. Our aim is to get this message across so we all can, together make a healthy Hindustan!”

About Swine Flu:

Swine influenza, or “swine flu”, is a highly contagious acute respiratory disease of pigs, caused by swine influenza H1N1 virus. The virus is spread among pigs by aerosols and direct and indirect contact. Pigs can carry the virus without showing any signs of the disease. The virus is transmitted from pigs to people and in some cases can be transmitted from human to human. The flu virus is most likely to spread among people who are in close proximity of pigs which are infected with the virus. The virus spreads among humans in much the same way as seasonal flu, via the mouth, nose or eyes. Transmission occurs in aerosols, droplets and indirect contact via hands and surfaces. Swine flu symptoms are very similar to seasonal influenza and generally include fever, fatigue, lack of appetite and coughing, although some people also develop a runny nose, sore throat, vomiting or diarrhoea


Lifebuoy recommends the following simple Hygiene Steps to reduce the risk of spreading Flu and Flu-like illnesses:

  • Avoid touching your face, nose, mouth or eyes with your hands, especially when you’ve been in public places. If you have to, make sure you wash hands with soap and water beforehand.

    Wash your hands often especially after blowing your nose, touching items that may be contaminated, or dealing with children and others more vulnerable to infection. You should wash your hands with soap under running water for at least 20 seconds and make sure you rinse and dry them so they don’t get re-contaminated

  • Keep yourself and your kitchen clean by washing your hands with soap and drying thoroughly: a) before preparing food, b) after touching raw food, especially meat, c) after going to the toilet

Written by sreelakshmi

25 May, 2009 at 3:30 pm

‘First ever World MS (Multiple Sclerosis) Day on 27 May 2009’

with 2 comments





The Multiple Sclerosis Society of India (MSSI), the only Society in India working for the persons suffering from Multiple Sclerosis (MS), recently announced that the first ever World MS Day will be held on Wednesday, 27 May 2009 (and the last Wednesday of May every year in future). As part of the global event, several awareness programmes are being arranged in coordination with the Multiple Sclerosis International Federation (MSIF), U.K. which has been instrumental in leading the global movement to improve the quality of life of people affected by MS and to support better understanding and treatment of MS.

The first ever World MS Day will unite individuals, groups and organisations in the global MS movement by providing them with an opportunity to participate in events and activities that will raise awareness of MS as a global issue, raise funds to support the work of the movement and call for greater international collaboration in MS research.

Multiple Sclerosis (MS) is a chronic progressive incurable disease of the central nervous system, in which the simplest everyday tasks can no longer be taken for granted.
It is not a killer disease but a crippling one, which happens to young adults between the ages of 18 – 35. According to a study conducted between 2005 and 2008 across 112 countries by MSIF and the World Health Organization (WHO), there are about two million people with MS in the world today. In India alone, it is estimated that there are 40,000 to 50,000 people afflicted with MS. Of these, the MSSI is currently serving approximately 300 MS patients in Mumbai and 3,000 all over India through their branches in Bangalore, Calicut, Chennai, Delhi, Hyderabad, Kolkata, Mangalore and Pune.

As part of a plan to raise awareness, the MSSI’s nine chapters across India will form human chains in their respective cities. The Mumbai Chapter will form a human chain at the Masina Hospital and will host a ceremony at which Dr Noshir Wadia, the ‘Father of Neurology in India’, will be felicitated for his dedicated support to the MS cause right from 1985. The event will also be graced with the presence of the renowned neurologist Dr Bhim Sen Singhal (Chief of MSSI All India Medical Panel), and will be attended by several MS patients, their families, doctors and supporters of the cause.

Speaking at a media meet, Mr Firdose Vandrevala, Hon. President of MSSI said, “As the only Society in India working towards the cause of helping the persons suffering from MS, it is our endeavour to increase awareness about this chronic disease. Since this disease cannot be detected easily, it is important that the patients connect with our branches across the country and seek the right guidance and medical assistance.”

As the Cause Ambassador of MSSI, well-known supermodel and actor Milind Soman said, “All of us have to globally join hands and in our own little way try to improve the quality of life of people affected by MS. International collaboration between MS societies will give us a better insight of MS and understanding of the challenges that MS brings into the lives of an MS person. As the Cause Ambassador of MS Society of India, I undertake the mission to increase the awareness about MS in my country and feel that we should all work in co-operation to achieve a worldwide solidarity for MS movement.”

Milind also plans to run the New York Marathon on 1 November 2009 and the London Marathon in April 2010 for the MSSI and Indian MS Patients.

Mr Firdose Vandrevala added, “At MSSI we also try to lighten some of the patient’s burden by providing various services like counselling, regular home physiotherapy, home nursing, home visits, medical reimbursements, their children’s School / College fees, donating mobility aids, air/water beds, incontinence products etc. We also help them to get disability certificates. Besides these we organize Annual Free Medical Camps, Seminars and Workshops and Recreational Programmes for patients and families.”

The press meeting was also addressed by other renowned dignitaries from the field of MS – Dr Noshir Wadia, (Advisor of MSS All India Medical Panel), Dr. Bhim Sen Singhal (Chief of MSSI All India Medical Panel), Mrs. Sheela M. Chitnis (National Hon. Secretary), Mrs. Anita Vesuvala (Hon. Secretary, Mumbai chapter) and an MS patient.

For more information on Multiple Sclerosis visit Websites: and



Written by sreelakshmi

25 May, 2009 at 2:27 pm

Bajaj Allianz Insurance posts both profits and growth for FY 08-09

with 2 comments

Bajaj Allianz Life Insurance and Bajaj Allianz General Insurance, one of the largest private insurers in both the life and non-life segment in India, have posted profits for the financial year 2008-09 despite the ongoing recessionary market conditions.

  • Profits
    • Bajaj Allianz General Insurance posted a profit before tax (PBT) of Rs 150 crore for the year 08-09 and the profit after tax (PAT) was Rs 95 crore.
    • Bajaj Allianz Life Insurance posted a profit of Rs 45 crore for the year 08-09 as against loss of Rs 16 crores in the previous year.
  • Premium Income & Number of policies
    • Bajaj Allianz General Insurance grew by 10% to garner Gross Written Premium (GWP) of Rs 2649 crore as compared to Rs 2404 crore in the last financial year 2007-08 while Bajaj Allianz Life Insurance grew by 9% garnering a premium of Rs 10624 crore with new business premium at Rs 4491 crore and Renewal Premium at Rs 6133 crores in the financial year 2008-09 as against GWP of Rs 9725 crore (comprising of New Business – Rs 6674 crore and Renewal Premium – Rs 3051 crore) in the financial year 2007-08.
    • Both companies continue to handle large volumes, Bajaj Allianz General Insurance has issued over 7.5 million policies and Bajaj Allianz Life Insurance has 7.4 million policies in force.
  • Capital Infused
    • Both the companies did not require any capital infusion in the year 2008-09 and maintained high solvency margin. As on 31st March 2009, Bajaj Allianz Life Insurance had a solvency margin of >250% and Bajaj Allianz General Insurance had a solvency margin of >160%.
    • Both the companies continue to be the most capital efficient in their respective businesses.
  • Assets Under Management
    • The Assets under Management (AUM) stood at Rs 17,157 crore, which is an increase of 26 % for Bajaj Allianz Life Insurance in the financial year 2008-09, one of the highest among the private life insurers in the insurance industry.

Speaking on the results posted by the companies, Kamesh Goyal, Country Manager, Allianz & CEO, Bajaj Allianz Life Insurance, said, “Prudent expense management, pursuing a sustainable growth model have ensured that we balance growth and profitability. In the last financial year, we had undertaken several initiatives to ramp up our customer service initiatives and launched several need-based products. The year 2009-10 would be challenging for the insurance industry due to slowdown in growth which will put enormous challenge to margins.”

Bajaj Allianz is one of the few private insurance companies that have posted a profit in the financial year 2008-09 posting a profit of Rs 45 crores for the life insurance business and Rs 95 crores for the general insurance business.

Written by sreelakshmi

24 May, 2009 at 11:14 pm